 | |
| Company type | Public |
|---|---|
| Traded as | BSE: 524494 NSE: IPCALAB |
| Industry | Pharmaceutical |
| Founded | 19 October 1949 as The Indian Pharmaceutical Combine Association Limited |
| Founder | K.B. Mehla Dr. N.S. Tibrawala |
| Headquarters | Mumbai, Maharashtra, India |
| Area served | Worldwide |
| Key people | Premchand Godha (MD) AK Jain (JMD) |
| Products | Pharmaceutical drugs, generic drugs, antiviral drugs, over-the-counter drugs, vaccines, |
| Revenue |  ₹5,896 crore (US$710 million) (FY22) |
| Net income |  ₹884 crore (US$110 million) (FY22) |
| Number of employees | 12000 (2015) |
| Subsidiaries | CCPL Software, Ipca Traditional Remedies |
| Website | www |
Ipca Laboratories Limited is an Indian multinational pharmaceutical company based in Mumbai. It produces theobromine, acetylthiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. It produces more than 150 formulations that include oral liquids, tablets, dry powders, and capsules.
History
It was founded by group of businessmen and medical professionals in 1949. In 1975, the management of the company was taken over by Amitabh Bachchan, Ajitabh Bachchan, Jaya Bachchan, M.R. Chandurkar, P.C. Godha. In 1997, the Bachchan family sold their 36% holding in Ipca Laboratories to, at the time, the company's four whole time directors.
In 2004, Forbes selected Ipca, for the second consecutive year as one among the first 200 'Best under a billion company' in Asia.
It also got certification from US Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA). On 29 Jan 2016 the FDA issued a warning letter, WL: 320-16-07, for failure to comply with good manufacturing processes (GMP) under section 21 of the code of federal regulations (21 CFR).
Products and operations
The various kinds of drug intermediates that the company manufactures include theobromine, acetylthiophene, and p-bromotoluene. It is present in over 36 countries of Asia, Africa, CIS, and South America, including Cambodia, Kazakhstan, Kenya, Mauritius, Myanmar, New-Zealand, Nigeria, Oman, Russia, Sri Lanka, Sudan, Tanzania, Ukraine, Vietnam and Yemen. The main activities of company are to produce and market pharmaceuticals and drugs. The various products of the company include formulations, drug intermediates, and active pharmaceutical ingredients (API).
References
- "Ipca Laboratories Ltd. :: Contact Us :: India Offices". Ipcalabs.com. Archived from the original on 13 November 2010. Retrieved 1 December 2010.
- ^ "Ipca Laboratories targets Rs 425cr turnover this year". Expressindia.com. 15 September 2000. Retrieved 2 December 2010.
- "Pawan Kothari". Expresspharmaonline.com. 31 August 2010. Retrieved 2 December 2010.
- ^ "Ipca Labs Q4 net profit declines 19% at Rs 130 crore on higher expenses". Business Standard. 24 May 2022. Retrieved 3 February 2023.
- "Ipca Laboratories Ltd plans to diversify into Ayurveda business". AyurvedNews.com. Archived from the original on 7 July 2011. Retrieved 2 December 2010.
- "Ipca Laboratories". Business.mapsofindia.com. Retrieved 1 December 2010.
- "Interview of Mr. AK Jain, Executive Director, Ipca Laboratories Ltd". Indiainfoline.com. Retrieved 1 December 2010.
- "IPCA Laboratories Ltd Term Buy Call: StocksIdea.com | TopNews". Topnews.in. 15 December 2009. Retrieved 1 December 2010.
- ^ "Ipca Laboratories Ltd Background details about Company Profile". Indiainfoline.com. 9 August 1988. Retrieved 1 December 2010.
- Tiwari, Vibha (7 February 1997). "Bachchans To Sell 36% Stake In Ipca Labs To Directors". Business Standard India. Retrieved 16 July 2022.
- "WL: 320-16-07". FDA.gov. Retrieved 16 February 2016.
